Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)

Study:

A Phase II Evaluation of Weekly Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Rationale:

Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

This phase II trial is studying how well docetaxel works in treating patients with recurrent or persistent endometrial carcinoma (cancer).

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Endometrial Cancer Drug: docetaxel Phase 2

Verified by Gynecologic Oncology Group January, 2014

Sponsored by: Gynecologic Oncology Group
Information provided by: Gynecologic Oncology Group
ClinicalTrials.gov identifier: NCT00085332

Study Type: Interventional

Study Design: Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44124
United States

Agustin Garcia, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site